STRIKEMOX™ CV 625

Amoxycillin is a semi-synthetic penicillin-class antibiotic that exerts its bactericidal effect by covalently binding to penicillin-binding proteins (PBPs) on the inner membrane of the bacterial cell wall. This binding irreversibly inhibits the transpeptidase enzyme activity responsible for cross-linking peptidoglycan strands — the structural backbone of bacterial cell walls. Disruption of peptidoglycan synthesis causes osmotic instability, cell wall rupture, and ultimately bacterial cell death.

Potassium Clavulanate acts as a suicide inhibitor of bacterial beta-lactamase enzymes. Many clinically relevant pathogens have developed resistance to amoxycillin by producing beta-lactamases — enzymes that cleave the beta-lactam ring of the antibiotic and render it inactive. Clavulanate binds irreversibly to these enzymes, forming a stable acyl-enzyme complex that permanently inactivates them. This protects the amoxycillin molecule from enzymatic degradation and restores its bactericidal activity against resistant strains.

The synergistic combination broadens the antimicrobial spectrum significantly, covering organisms such as beta-lactamase-producing H. influenzae, M. catarrhalis, S. aureus, E. coli, Klebsiella pneumoniae, and Bacteroides fragilis — pathogens commonly implicated in respiratory, dental, and soft tissue infections.

STRIKEMOX™ CV 625 is indicated for bacterial infections caused by amoxycillin-susceptible and beta-lactamase-producing organisms across multiple clinical specialities.

Respiratory Infections: Community-acquired pneumonia, acute exacerbations of chronic obstructive pulmonary disease (COPD), acute bacterial sinusitis, acute otitis media, tonsillitis, and pharyngitis. Particularly effective for pulmonologist-managed cases involving resistant H. influenzae and M. catarrhalis.

Dental Infections: Periapical abscess, periodontitis, acute necrotising ulcerative gingivitis, and post-surgical dental infections where mixed aerobic-anaerobic flora is present. The coverage of Bacteroides species makes this combination especially valuable in dental practice.

Urogenital Infections: Uncomplicated and complicated urinary tract infections, urethritis, and pelvic inflammatory disease as part of a broader regimen.

Skin and Soft Tissue: Animal bites, infected wounds, cellulitis, erysipelas, and diabetic foot infections where polymicrobial contamination is likely.

Bone and Joint Infections: Osteomyelitis and septic arthritis caused by susceptible staphylococci and streptococci in combination with other agents.

Intra-Abdominal Infections: As part of combination therapy for peritonitis and biliary tract infections involving gram-negative anaerobic organisms.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.